陳健弘2006-07-262018-07-112006-07-262018-07-112005http://ntur.lib.ntu.edu.tw//handle/246246/23713Hepatocellular carcinoma (HCC) is a major cause of cancer-related death in Taiwan. The major risk factors identified in the development of HCC are persistent hepatitis caused by infection of hepatitis B virus (HBV) or hepatitis C virus (HCV). Hepatocarcinogenesis was preceded by a long period of subclinical stage, and diagnosis of this disease was often at late stage. The 5-year survival rate for HCC patients is below 50%. Current methods for the diagnosis of HCC main rely on serological markers such as alpha-fetoprotein (AFP) and certain liver enzymes, together with ultrasonography. However, AFP index has poor specificity. Searching new markers for HCC diagnosis and monitoring this disease is urgent. To identify tumor antigens presented by HCC, we used a proteomic approach combined serological and 2D-SDS/PAGE techniques. HCC patient sera serve as antibodies, and tumor tissue protein as antigens. Numerous circulating anti-tumor antibodies have been described in the serum of patients for a variety of cancers. In this study, 20 HCC serum samples and 10 HCC surgical tumor tissues were collected. Tumor proteins were extracted and separated by 2D-SDS/PAGE, and then were transferred to PVDF membranes for immunodetection. Comparison of autoantibody responses generated by HCC patients and normal subjects made us identify the differentially HCC candidate antigen spots. Following in-gel digestion and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF), we have identified 27 candidate antigens that may be involved in chronic hepatitis B and HBV-related HCC. Characterization of these candidate antigens may provide insight the carcinogenesis of HCC and improve diagnosis.application/pdf710765 bytesapplication/pdfzh-TW國立臺灣大學醫學院內科[SDGs]SDG3reporthttp://ntur.lib.ntu.edu.tw/bitstream/246246/23713/1/932314B002228.pdf